Similar articles

• Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.

  Nam HS, Koh WJ, Kwon OJ, Cho SN, Shim TS. Nam HS, et al. Int J Antimicrob Agents. 2009 Jan;33(1):92-3. doi: 10.1016/j.ijantimicag.2008.06.014. Epub 2008 Sep 11. Int J Antimicrob Agents. 2009. PMID: 18789655 No abstract available.
• How should we treat "difficult" multidrug-resistant tuberculosis?

  Yew WW, Leung CC. Yew WW, et al. Chest. 2009 Feb;135(2):587-588. doi: 10.1378/chest.08-1776. Chest. 2009. PMID: 19201730 No abstract available.
• Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

  Yew WW, Chang KC, Chau CH. Yew WW, et al. J Antimicrob Chemother. 2009 Nov;64(5):1119; author reply 1119-20. doi: 10.1093/jac/dkp291. Epub 2009 Aug 8. J Antimicrob Chemother. 2009. PMID: 19666903 No abstract available.
• Vancomycin-resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid.

  Ang JY, Lua JL, Turner DR, Asmar BI. Ang JY, et al. Pediatr Infect Dis J. 2003 Dec;22(12):1101-3. doi: 10.1097/01.inf.0000101784.83146.0c. Pediatr Infect Dis J. 2003. PMID: 14688576 Review.
• Combined retrospective analysis of seven phase II and III trials of the efficacy of linezolid in the treatment of pneumonia caused by multidrug-resistant Streptococcus pneumoniae.

  Ijzerman MM, Tack KJ, Huang DB. Ijzerman MM, et al. Clin Ther. 2010 Dec;32(13):2198-206. doi: 10.1016/S0149-2918(11)00023-3. Clin Ther. 2010. PMID: 21316536 Review.